Insulin patents and market exclusivities: unresolved issues

Lancet Diabetes Endocrinol. 2016 Feb;4(2):98. doi: 10.1016/S2213-8587(15)00496-9.

Authors

Warren Kaplan¹, Richard Laing², Marg Ewen³, David Beran⁴

Affiliations

¹ WHO Collaborating Center for Pharmaceutical Policy, Department of Global Health, Boston University School of Public Health, Boston, MA 02118, USA. Electronic address: wak@bu.edu.
² Boston University School of Public Health, Boston, MA, USA.
³ Health Action International Global, Amsterdam, Netherlands.
⁴ Division of Tropical and Humanitarian Medicine, Faculty of Medicine, University of Geneva and Geneva University Hospitals, Geneva, Switzerland.

PMID: 26825233
DOI: 10.1016/S2213-8587(15)00496-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Drugs, Generic / economics*
Humans
Hypoglycemic Agents / economics*
Insulin / economics*

Substances

Drugs, Generic
Hypoglycemic Agents
Insulin